Myricx Bio
Myricx Bio is a UK biotech company developing a novel class of payloads for antibody-drug conjugates (ADCs) based on N-myristoyltransferase inhibitors (NMTis). These ADCs target cancer cell survival, addressing unmet needs in oncology with demonstrated preclinical efficacy and safety. The company is a spinout from Imperial College London and the Francis Crick Institute.
Funding Round: Series A
Funding Amount: $114M
Date: 08-Jul-2024
Investors: Novo Holdings, Abingworth, British Patient Capital, Eli Lilly & Company, Sofinnova Partners, Brandon Capital
Markets: Biotechnology, Oncology, Pharmaceuticals, Life Science, Therapeutics
HQ: London, England, United Kingdom
Founded: 2019
Website: https://myricxbio.com/
LinkedIn: https://www.linkedin.com/company/myricx-bio
Crunchbase: https://www.crunchbase.com/organization/myricx-pharma
Leave a Comment
Comments
No comments yet.